Biovica, specializing in blood-based cancer monitoring, today announced that the Japanese Patent Office has granted a new patent covering the use of TKa in relation to immune checkpoint inhibitor treatment in cancer patients.
The granting expands Biovica’s patent protection in immuno-oncology from Europe to Japan, adding another important oncology market to the company’s growing intellectual property position. Biovica was granted a corresponding European patent in 2025 and continues to pursue patent protection in other key markets, including the US and China.
Immuno-oncology is one of the largest and fastest-growing areas in cancer treatment, with immune checkpoint inhibitors representing a multi-billion-dollar global market. The expanded patent protection strengthens Biovica’s position in a commercially important field and supports the broader potential for DiviTum® TKa.
The patent protects the use of TKa to help identify which cancer patients are more likely to benefit from immune checkpoint inhibitor treatment.
“This is an important step in strengthening Biovica’s intellectual property position in immuno-oncology. It further supports our ambition to make DiviTum TKa more broadly available as a blood-based tool that can help guide cancer treatment globally and support pharmaceutical companies in cancer drug development,” said Theis Kipling, CEO of Biovica.